Revenues increased approximately 32 percent to $254 million, as compared to $192.4 million reported for the second quarter of 2003.
Invitrogen said that the revenue growth included a 19 percent increase in its BioDiscovery unit, due principally to its Molecular Probes acquisition. It also attributed a 53 percent increase in revenues for its BioProduction products to its acquisition of BioReliance and solid customer demand for its cell culture products.
Net income for the second quarter also increased, to $19.7 million, from $16.9 million for Q2 of 2003.